NeoGenomics, Inc.

257 articles about NeoGenomics, Inc.

• NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

  11/14/2023

  NeoGenomics, Inc., a leading oncology testing services company, announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City.

• NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

  10/24/2023

  NeoGenomics, Inc., a leading oncology testing services company, announced the commercial availability of two new tests, expanding its cancer portfolio of innovative products.

• NeoGenomics Reports Second Quarter 2023 Results

  8/8/2023

  NeoGenomics, Inc. today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022.

• NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

  7/27/2023

  NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection.

• NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

  7/18/2023

  NeoGenomics, Inc.today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023.

• NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

  6/29/2023

  NeoGenomics, Inc. today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.

• NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

  6/15/2023

  NeoGenomics, Inc. announced that its RaDaR® assay, a personalized liquid biopsy for minimal/molecular residual disease and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California.

• NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

  6/5/2023

  NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

• NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

  6/1/2023

  NeoGenomics, Inc. today announced the company will be participating in the upcoming Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California.

• NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

  5/30/2023

  NeoGenomics, Inc. today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6 in Chicago, Illinois.

• NeoGenomics Reports First Quarter 2023 Results

  5/8/2023

  NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023.

• NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference

  5/3/2023

  NeoGenomics, Inc.today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada.

• NeoGenomics to Announce First Quarter 2023 Financial Results

  4/17/2023

  NeoGenomics, Inc. announced today that it will release its first quarter 2023 financial results on Monday, May 8, 2023.

• NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

  4/11/2023

  NeoGenomics, Inc. today announced that members of its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 11:00am ET.

• NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023

  4/6/2023

  NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the company and its collaborators will present a total of nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023 in Orlando, Florida.

• NeoGenomics to Host Investor Day on April 4, 2023

  3/27/2023

  NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host an Investor Day on Tuesday, April 4, 2023, starting at 8:00 am ET.

• Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

  3/22/2023

  Massive Bio, Inc. and NeoGenomics, Inc. today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world.

• NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

  3/16/2023

  NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR assay, a liquid biopsy test for molecular/minimal residual disease (MRD).

• NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP

  3/13/2023

  NeoGenomics, Inc. announced today the expansion of their next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of multiple tests, including Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor cancers, and Neo Comprehensive - Myeloid Disorders, a CGP for myeloid neoplasms.

• NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference

  2/28/2023

  NeoGenomics, Inc. today announced that Chris Smith, chief executive officer of NeoGenomics, and Jeff Sherman, chief financial officer, will participate in a fireside chat at the 44th Annual Raymond James Institutional Investors Conference on Monday, March 6, 2023 at 7:30am ET.